Autolus Therapeutics plc
- AUTL
- NASDAQ
- Biotechnology
- CAR-T/Cell Therapy
- Oncology Immunotherapy
$1.62
Today +1.89%Quote Oct 20, 2026, 02:09 PM UTC
−18.04%over the last month
Max drawdown −21.7%From 1-month high −21.7%3 months +8.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Autolus Therapeutics
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL).
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
752
Market value
$431.2M
Quote Oct 20
Floor
$1.53
5.3% below price
Resistance
$1.67
3.1% above price
Price vs analyst targets
14 analysts
Lowest target
$7.60Highest target
$11.00
$7.60Highest target
$11.00
- Price $1.62
- Average target $8.87
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 448% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about AUTLPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free